Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
Joost H. van den Berg(The Netherlands Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center), Remko Schotte(AIMM Therapeutics (Netherlands)), Pia Kvistborg(The Netherlands Cancer Institute), Annelies Jorritsma‐Smit(The Netherlands Cancer Institute), Marit M. van Buuren(The Netherlands Cancer Institute), Matthias Karger(The Netherlands Cancer Institute), Noor A. M. Bakker(Leiden University), Raquel Gomez-Eerland(The Netherlands Cancer Institute), Renate de Boer(The Netherlands Cancer Institute), Bianca Heemskerk(The Netherlands Cancer Institute), Michel W.J.M. Wouters(The Netherlands Cancer Institute), Jos H. Beijnen(The Netherlands Cancer Institute), Nienke van Rooij(The Netherlands Cancer Institute), Bastiaan Nuijen(The Netherlands Cancer Institute), Loes M. Pronk(The Netherlands Cancer Institute), Christian U. Blank(The Netherlands Cancer Institute), Hergen Spits(Erasmus MC Cancer Institute), Maaike van Zon(The Netherlands Cancer Institute), Samira Michels(The Netherlands Cancer Institute), Ton N. Schumacher(Leiden University Medical Center), Marnix H. Geukes Foppen(The Netherlands Cancer Institute), Henk Mallo(The Netherlands Cancer Institute)
Cited by 196
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k